BioSpace News Archive

Zeon Corporation, through its subsidiary Zeon Specialty Materials Inc., has purchased 100% of the shares of Edge Precision Manufacturing, Inc., a manufacturer of micro featured thermoplastic devices, from shareholders including venture capital funds managed by U.S. investment company Anzu Partners, LLC, on December 28, 2022.

Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces the completion of its previously announced stock-for-stock merger transaction with Catheter Precision, Inc., a company focused on the cardiac electrophysiology market.

Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical industries, is pleased to announce a partnership with ILC Dover, a leader in the innovative design and production of solutions for biopharmaceutical, pharmaceutical and medical device markets.

Immersion Corporation announced it has signed a license agreement with Vishay Intertechnology, Inc. to bundle Immersion haptic patent licenses for purchasers of Vishay’s solenoid-based haptic actuators, streamlining the design-in process for Vishay’s game-changing technology.

Acadia Pharmaceuticals Inc. announced the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announces publication of two new studies that show positive clinical outcomes using the Equinoxe® shoulder preoperative Planning App and ExactechGPS® shoulder intraoperative navigation system.

Therapeutic Solutions International (TSOI) announced today identification and patent filing of a previously unexpected discovery that responsiveness to JadiCell stem cell therapy appears to correlate with alternations of a specific type of B cell producing the cytokine interleukin-10 and possessing unique surface markers.

UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announces positive topline results from the IASOS Phase 2b study of oral orismilast in adult patients with moderate to severe psoriasis.

Kiora is advancing a pipeline of therapeutics for rare and underserved ophthalmic diseases -

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the “Subsidiary” or “PAPL”) for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids (“Sol-Gel License”).